Global Erythropoietin Stimulating Agents Market Size, Trends & Analysis - Forecasts To 2026 By Type (Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Others), By Application (Anti-retroviral Treatment, Renal Disorders, Neural Diseases, Cancer, Others), By Region (North America, Europe, Asia Pacific, MEA, CSA), Vendor Landscape, End User Landscape and Company Market Share Analysis & Competitor Analysis
Erythropoietin Stimulating Agents Market Insights
The global erythropoietin stimulating agents market is expected to generate revenue amounting to USD 11.90 billion in 2020, and is projected to reach to USD 20.80 billion by 2026, growing at a CAGR of 9.75% over the forecast period. Rising incidence of chronic diseases such as CKD and cancer resulting in anemia is one of the major factor driving the market for erythropoietin stimulating agents during the forecast period. According to the data published by the National Heart, Lung, and Blood Institute of the U.S. Department of Health & Human Services, more than 3 million people are affected by anemia every year and this number is expected to increase during the forecast period (2020-2026). Erythropoietin Stimulating Agents have been approved for the treatment of anemia due to chronic kidney failure, chemotherapy, HIV, and for the treatment of reduced red blood cells during critical surgical procedures. Increasing number of cancer treatments across various regions including North America, Europe, Asia Pacific, and Central & South America is further projected to propel the market growth of Erythropoietin stimulating agents. However, stringent regulatory guidelines and adverse side effects, are likely to hamper the market growth during the forecast period.
Erythropoietin Stimulating Agents Market Size: By Segmentation
The global erythropoietin stimulating agents market is segmented on the basis of type into epoetin alfa, epoetin beta, and darbepoetin alfa among others. The epoetin alfa segment is expected to hold the largest market share in the global erythropoietin stimulating agents market during the forecast period. Epoetin alfa is a human erythropoietin produced in cell culture using recombinant DNA technology. Epoetin alfa products are used to treat anemia in people with chronic kidney failure. Growing number of cancer patients and increasing number of surgeries is expected to drive the market growth for epoetin alfa segment during the forecast period. Epoetin-beta and epoetin-zeta are expected to grow at a significant CAGR during the forecast period owing to associated benefits such as longer half-life and enhanced therapeutic effects.
On the basis of application, the global erythropoietin stimulating agents market is segmented into cancer, renal disorders, anti-retroviral treatment, and neural diseases among others. The cancer segment is expected to hold the largest market share and is also expected to grow at a significant CAGR during the forecast period. Anemia is observed in majority of patients undergoing cancer treatment. Anemia results in fatigue, weakness, and depression, which severely reduces the quality of life of cancer patients. Increase in cancer patients undergoing chemotherapy is expected to propel the market growth for erythropoietin stimulating agents during the forecast period. Growing healthcare expenditure across the globe to treat cancer patients is also driving the market growth.
Erythropoietin Stimulating Agents Market Size: By Region
On the basis of region, the market of erythropoietin stimulating agents is segmented into North America, Europe, Asia Pacific, Central & South America, and Middle East & Africa. The North America region is expected to dominate the market and is also estimated to expand at a rapid pace during the forecast period. Rise in various chronic diseases, such as chronic kidney disease (CKD), cancer, neural, and HIV infections among others in the region is driving the market growth for erythropoietin stimulating agents. According to the Centers for Disease Control and Prevention (CDC), it is estimated that more than 10% of adults in the United States suffer from CKD. The increasing number of people at high risk for CKD is expected to propel the market growth. According to the data published CDC, in 2018 more than 29 million people suffered from diabetes, and about 86 million were in the pre-diabetic stage.
Erythropoiesis-stimulating agents are medications which stimulate the bone marrow to make red blood cells. They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS. ESAs are usually given to patients who have chronic kidney disease or end-stage renal (kidney) disease. They are given to the patients usually who have lower hemoglobin levels. ESAs are also prescribed for patients who have cancer.
In May 2018, Pfizer Inc launched RETACRIT (epoetin alfa-epbx), a biosimilar to Epogen and Procrit (epoetin alfa) 1 approved by United States (U.S.) Food and Drug Administration (FDA). RETACRIT is the first biosimilar erythropoiesis-stimulating agent (ESA) to be approved in the U.S.
Erythropoietin Stimulating Agents Market: Share & Competitor Analysis
Some of the key players operating in the erythropoietin stimulating agents market include: Biocon Limited, Celltrion Inc., F. Hoffmann-La Roche Ltd., Amgen Inc., BioSidus, Johnson and Johnson, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., and Thermo Fisher Scientific, among others.
Please note: This is not an exhaustive list of companies profiled in the report.
Erythropoietin Stimulating Agents Market: By Type
Erythropoietin Stimulating Agents Market: By Application
Erythropoietin Stimulating Agents Market: By Region
The global Erythropoietin Stimulating Agents Market has been studied from the year 2017 till 2026. However, the CAGR provided in the report is from the year 2018 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply side analysis for the Erythropoietin Stimulating Agents Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the companies and customer analytics.
80% of our clients seek made-to-order reports. How do you want us to tailor yours?